Dyne Therapeutics (DYN) Other financing activities (2020 - 2026)
Dyne Therapeutics (DYN) posted quarterly Other financing activities of $737000.0 for Q2 2026, down 62.63% year-over-year from $2.0 million in Q2 2025, and down 43.78% quarter-over-quarter from $1.3 million in Q1 2026.
Dyne Therapeutics (DYN) Other financing activities (2020 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Other financing activities for 7 consecutive years, with $737000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Other financing activities fell 62.63% year-over-year to $737000.0; the TTM figure through Jun 2026 stood at $7.5 million (down 69.07% YoY), while the FY2025 annual figure was $8.0 million, down 78.29% from the prior year.
- Other financing activities fell to $737000.0 in Q2 2026 per DYN's latest filing, from $1.3 million in the prior quarter.
- Across five years, Other financing activities topped out at $18.0 million in Q3 2024 and bottomed at $18000.0 in Q1 2022.
- Historically, Other financing activities has averaged $2.7 million across 5 years, with a median of $750500.0 in 2023.
- Annual changes were most pronounced in 2024 — Other financing activities soared 3866.74% — and 2025, when it slumped 94.61%.
- Dyne Therapeutics' Other financing activities stood at $342000.0 in 2022, then sank by 56.73% to $148000.0 in 2023, then jumped by 2356.76% to $3.6 million in 2024, then slipped by 7.43% to $3.4 million in 2025, then plunged by 78.1% to $737000.0 in 2026.
- Business Quant data shows DYN's Other financing activities at $737000.0 in Q2 2026, $1.3 million in Q1 2026, and $3.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 737,000.00 |
| Jun 30, 2026 | 737,000.00 |
| Mar 31, 2026 | 1.31 Mn |
| Mar 31, 2026 | 1.31 Mn |
| Dec 31, 2025 | 3.37 Mn |
| Dec 31, 2025 | 3.37 Mn |
| Sep 30, 2025 | 2.07 Mn |
| Sep 30, 2025 | 2.07 Mn |
| Jun 30, 2025 | 1.97 Mn |
| Jun 30, 2025 | 1.97 Mn |
| Mar 31, 2025 | 588,000.00 |
| Mar 31, 2025 | 588,000.00 |
| Dec 31, 2024 | 3.64 Mn |
| Dec 31, 2024 | 3.64 Mn |
| Sep 30, 2024 | 18.01 Mn |
| Sep 30, 2024 | 18.01 Mn |
| Jun 30, 2024 | 4.28 Mn |
| Jun 30, 2024 | 4.28 Mn |
| Mar 31, 2024 | 10.92 Mn |
| Mar 31, 2024 | 10.92 Mn |